Skip to content
Peptilyze
CompoundsShopsCompareGuidesMethod
Hormonal & reproductive

Melanotan I studies

156 journal papers mention Melanotan I in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Melanotan I is safe, effective or approved for any use.

Compare Melanotan I prices, from €17.99 →

Papers
156
126 articles, 30 reviews
Earliest paper
1995
Most papers in 2024 (17)
Open access
50%
free to read somewhere
Reviews
19%
of all papers listed

What kind of studies

Of 121 papers in PubMed that mention Melanotan I in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials4
  • Other clinical trials8
  • Meta-analyses and systematic reviews3
  • Other reviews48
  • Case reports7
  • Animal studies only4
  • Studies in humans85

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Registered clinical studies

Studies on ClinicalTrials.gov that mention Melanotan I in their intervention details. A registration says a study is planned or running, not what it found.

Registered
23
Completed
18
Ongoing or planned
1
Phase 1
4
Phase 2
13
Phase 3
6
  1. Pharmacokinetics of Afamelanotide in Erythropoietic Protoporphyria Patients

    NCT06388642CompletedPhase 1 / Phase 2started 2024-03-07

  2. A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

    NCT06109649Active, not recruitingPhase 3started 2023-10-11

  3. Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)

    NCT05854784CompletedPhase 2started 2023-03-28

  4. Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

    NCT04525157CompletedPhase 2started 2014-06-06

  5. A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

    NCT05370235Status unknownPhase 2started 2022-03-28

The five most recently updated studies. See all 23 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.

Papers per year

1997 to 2026, peak 17 papers in a year. The latest year may still be incomplete.

1997: 2 papers1998: 1 papers1999: 1 papers2000: 2 papers2001: 1 papers2002: 0 papers2003: 0 papers2004: 0 papers2005: 0 papers2006: 2 papers2007: 0 papers2008: 0 papers2009: 6 papers2010: 7 papers2011: 7 papers2012: 5 papers2013: 5 papers2014: 7 papers2015: 10 papers2016: 6 papers2017: 3 papers2018: 3 papers2019: 5 papers2020: 8 papers2021: 11 papers2022: 6 papers2023: 12 papers2024: 17 papers2025: 12 papers2026: 14 papers19972026

Where it is published

  1. British Journal of Dermatology8 papers
  2. Journal of the American Academy of Dermatology7 papers
  3. Reactions Weekly6 papers
  4. JAMA Dermatology5 papers
  5. Clinical and Experimental Dermatology4 papers

The papers

ShowAllOpen accessReviews

Most citedName in the title

  1. Afamelanotide for Erythropoietic Protoporphyria

    Janneke G. Langendonk, Manisha Balwani, Karl E. Anderson et al. · New England Journal of Medicine · 2015

    Randomized trialOpen access282 citationsRead the open copy →

  2. Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo

    Henry W. Lim, Pearl E. Grimes, Oma N. Agbai et al. · JAMA Dermatology · 2014

    Randomized trialOpen access184 citationsRead the open copy →

  3. Controlled-Release Delivery System for the α-MSH Analog Melanotan-I Using Poloxamer 407

    Renu Bhardwaj, James Blanchard · Journal of Pharmaceutical Sciences · 1996

    Animal study161 citations

  4. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria

    Gianfranco Biolcati, E. Marchesini, Fiammetta Sorge et al. · British Journal of Dermatology · 2014

    Study in humansOpen access · CC BY-NC-ND102 citationsRead the open copy →

  5. The Efficacy of Afamelanotide and Narrowband UV-B Phototherapy for Repigmentation of Vitiligo

    Pearl E. Grimes, Iltefat H. Hamzavi, Mark Lebwohl et al. · JAMA Dermatology · 2012

    Case report102 citations

  6. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders

    Elisabeth Irene Minder, Jasmin Barman‐Aksözen, Xiaoye Schneider‐Yin · Clinical Pharmacokinetics · 2017

    Review65 citations

  7. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

    Debby Wensink, Margreet A. E. M. Wagenmakers, Jasmin Barman‐Aksözen et al. · JAMA Dermatology · 2020

    Study in humansOpen access49 citationsRead the open copy →

  8. In vitro characterization and in vivo release profile of a poly (d,l-lactide-co-glycolide)-based implant delivery system for the α-MSH analog, melanotan-I

    Renu Bhardwaj, J. Blanchard · International Journal of Pharmaceutics · 1998

    47 citations

  9. Skin Pigmentation and Pharmacokinetics of Melanotan-I in Humans

    Sydney O. Ugwu, James D. Blanchard, Robert T. Dorr et al. · Biopharmaceutics & Drug Disposition · 1997

    Randomized trial44 citations

  10. Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria

    Debby Wensink, Margreet A. E. M. Wagenmakers, Janneke G. Langendonk · Expert Review of Clinical Pharmacology · 2021

    ReviewOpen access · CC BY-NC-ND43 citationsRead the open copy →

  11. Afamelanotide, an agonistic analog of α-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria

    Elisabeth Irene Minder · Expert Opinion on Investigational Drugs · 2010

    Review41 citations

  12. In vitro evaluation of Poly(d,l-lactide-co-glycolide) polymer-based implants containing the α-melanocyte stimulating hormone analog, Melanotan-I

    Renu Bhardwaj, James D. Blanchard · Journal of Controlled Release · 1997

    37 citations

  13. Afamelanotide: A Review in Erythropoietic Protoporphyria

    Esther S. Kim, Karly P. Garnock-Jones · American Journal of Clinical Dermatology · 2016

    Review34 citations

  14. Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians

    Joseph Jia Hong Toh, Sai Yee Chuah, Anjali Jhingan et al. · Journal of the American Academy of Dermatology · 2020

    Randomized trial32 citations

  15. Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study

    Jasmin Barman‐Aksözen, Michèle Nydegger, Xiaoye Schneider‐Yin et al. · Orphanet Journal of Rare Diseases · 2020

    Study in humansOpen access · CC BY31 citationsRead the open copy →

  16. Advances in the management of erythropoietic protoporphyria – role of afamelanotide

    Ashley R. Lane, Jerome T. McKay, Herbert L. Bonkovsky · The Application of Clinical Genetics · 2016

    ReviewOpen access · CC BY-NC27 citationsRead the open copy →

  17. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria

    Elisabeth Irene Minder, Xiaoye Schneider‐Yin · Expert Review of Clinical Pharmacology · 2014

    Review24 citations

  18. Indications and Limitations of Afamelanotide for Treating Vitiligo

    Thierry Passeron · JAMA Dermatology · 2015

    Study in humans19 citations

  19. Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide

    Debby Wensink, Margreet A. E. M. Wagenmakers, J.H.P. Wilson et al. · The Journal of Dermatology · 2022

    Study in humansOpen access · CC BY14 citationsRead the open copy →

  20. Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: a dose-ranging study

    Norman S. Levine, R T Dorr, Ga Ertl et al. · Journal of Dermatological Treatment · 1999

    13 citations

  21. Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications

    Jessica Wu, Ronald Cotliar · Journal of Drugs in Dermatology · 2021

    Review12 citations

  22. A bioassay for the detection of neutralizing antibodies against the α-melanocyte stimulating hormone analog afamelanotide in patients with erythropoietic protoporphyria

    Rebecca Spichty, Mirjam Balimann, Jasmin Barman‐Aksözen et al. · Journal of Pharmaceutical and Biomedical Analysis · 2012

    Study in humans10 citations

  23. Pharmacologic Response of a Controlled-Release PLGA Formulation for the Alpha-Melanocyte Stimulating Hormone Analog, Melanotan-I

    Renu Bhardwaj, Mac E. Hadley, Robert T. Dorr et al. · Pharmaceutical Research · 2000

    Animal study10 citations

  24. Afamelanotide in protoporphyria and other skin diseases: a review

    Adriana Polańska, Joanna Wegner, Paula Nutbohm et al. · Advances in Dermatology and Allergology · 2024

    ReviewOpen access9 citationsRead the open copy →

  25. Indications and Limitations of Afamelanotide for Treating Vitiligo—Reply

    Henry W. Lim, Pearl E. Grimes, Mark Lebwohl · JAMA Dermatology · 2015

    Study in humans9 citations

  26. Evaluation of the Immunogenicity of the Synthetic α-Melanocyte-Stimulating Hormone (α-MSH) Analogue Afamelanotide ([Nle4- D -Phe7]-α-MSH, Scenesse®) in Erythropoietic Protoporphyria Patients by ELISA Detecting Both Anti-Afamelanotide and Anti-α-MSH Antibodies

    Stephan Lengweiler, Saskia Kreim, Jasmin Barman‐Aksözen et al. · Skin Pharmacology and Physiology · 2014

    Clinical trial · Phase 29 citations

  27. Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria

    Anna‐Elisabeth Minder, Xiaoye Schneider‐Yin, Henryk Zulewski et al. · Life · 2023

    Open access · CC BY8 citationsRead the open copy →

  28. Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study

    Anna‐Elisabeth Minder, Jasmin Barman‐Aksözen, Mathias Schmid et al. · Therapeutic Advances in Rare Disease · 2021

    Open access · CC BY-NC8 citationsRead the open copy →

  29. Pseudoleucoderma After Injections of Afamelanotide in a Patient with Atopic Dermatitis

    W. von Bartenwerffer, G Siebenhaar, N Hunzelmann · Acta Dermato Venereologica · 2011

    Case reportOpen access · CC BY-NC8 citationsRead the open copy →

  30. German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP )

    Bernhard Homey, Kathrin Schelonke, C Schlegel et al. · Photodermatology Photoimmunology & Photomedicine · 2025

    Study in humansOpen access · CC BY-NC-ND7 citationsRead the open copy →

  31. Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort

    Rebecca Karp Leaf, Hetanshi Naik, Paul Yanning Jiang et al. · Life · 2024

    Open access · CC BY6 citationsRead the open copy →

  32. Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study

    Marissa S. Ceresnie, Lindsey Mohney, Dayoung Ko et al. · Journal of the American Academy of Dermatology · 2022

    Study in humans5 citations

  33. Afamelanotide

    Elisabeth Irene Minder · Drugs of the Future · 2010

    5 citations

  34. The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

    Louisa G. Kluijver, Mitra Nekouei Shahraki, Margreet A.E.M. Wagenmakers et al. · British Journal of Dermatology · 2024

    Study in humansOpen access · CC BY4 citationsRead the open copy →

  35. A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial

    Vimal Stanislaus, Anthony W. Kam, Lily Murphy et al. · BMC Neurology · 2023

    Clinical trial · Phase 2Open access · CC BY4 citationsRead the open copy →

  36. Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide

    Mariachiara Arisi, Mariateresa Rossi, Chiara Rovati et al. · Photochemical & Photobiological Sciences · 2021

    Study in humansOpen access · CC BY3 citationsRead the open copy →

  37. From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria

    Anna‐Elisabeth Minder, Jasmin Barman‐Aksözen · JAAD Case Reports · 2025

    Case reportOpen access · CC BY2 citationsRead the open copy →

  38. Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective

    Robert S Dawe, Alastair C. Kerr, Ewan Eadie et al. · Clinical and Experimental Dermatology · 2025

    Open access2 citationsRead the open copy →

  39. Erythropoietic protoporphyria and afamelanotide: a patient’s perspective

    Marese O’Reilly, Victoria A. McGuire, Robert S. Dawe · Clinical and Experimental Dermatology · 2023

    Study in humansOpen access2 citationsRead the open copy →

  40. Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients

    Magdalena Seidl‐Philipp, Hanna Schratter, Johanna Auer et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026

    Open access · CC BY-NC1 citationsRead the open copy →

LatestName in title or abstract

  1. ‘Millions of superheated needles’: a patient’s experience of erythropoietic protoporphyria

    Mary-Catherine Walsh, Sarah O’Mahony, Ronan Brennan · Clinical and Experimental Dermatology · 2026

  2. Acute impact of afamelanotide on UVR erythemal and melanogenic responses in healthy humans in vivo: an exploratory study

    Liezel L. Griffin, Orsolya Kiss, Poonam Halai et al. · Photochemical & Photobiological Sciences · 2026

    Study in humansOpen access · CC BYRead the open copy →

  3. Erythropoetische Protoporphyrie im Kindesalter – eine interdisziplinäre Übersicht für die Praxis

    Moritz Toenne, T. Schaefer, Karolin Schaefer · Monatsschrift Kinderheilkunde · 2026

  4. A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023

    Natalia Maverakis, Zachary J Jaeger, Delphine J. Lee · Cureus · 2026

    ReviewOpen access · CC BYRead the open copy →

  5. Isopropanol‐Dimethyl Sulfoxide, as a Green Solvent Mixture for Solid‐Phase Peptide Synthesis

    Sikabwe Noki, Rajan Sharma, Beatriz G. de la Torre et al. · Chemistry - Methods · 2026

    Open access · CC BYRead the open copy →

  6. Afamelanotide

    Reactions Weekly · 2026

  7. Afamelanotide improves quality of life and light tolerance in Austrian erythropoietic protoporphyria patients

    Magdalena Seidl‐Philipp, Hanna Schratter, Johanna Auer et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2026

    Open access · CC BY-NC1 citationsRead the open copy →

  8. New and currently investigated pharmacotherapies for the erythropoietic protoporphyrias: spotlight on dersimelagon and bitopertin

    Jasmin Barman‐Aksözen, Francesca Granata, Sebastian Wäscher et al. · Expert Opinion on Pharmacotherapy · 2026

    ReviewOpen access · CC BY-NC-NDRead the open copy →

  9. Adjunctive use of Polypodium leucotomos extract in patients with erythropoietic protoporphyria: An exploratory study

    Nayha P. Shetty, Rebecca L. Quiñonez, Marissa S. Ceresnie et al. · Photochemistry and Photobiology · 2026

    Clinical trialOpen accessRead the open copy →

  10. Congenital Erythropoietic Porphyria with Persistent Severe Biochemical Abnormalities and a Non-Mutilating Clinical Course: A Case Report

    Supriya Peshin, Kaneez Khan, Ehab Takrori et al. · Reports — Medical Cases Images and Videos · 2026

    Case reportOpen access · CC BYRead the open copy →

  11. Beyond Janus kinases: Targeted Cytokine and Kinase Modulators for Refractory Vitiligo

    E. Ip, Michelle A. Rodrigues · Dermatological Reviews · 2026

    1 citations

  12. An Original PEG‐Functionalized PS Resin Enables Synthesis of Difficult Peptides: Application to Tirzepatide

    Ashish Kumar, Peter K. Kabwe, Mahama Alhassan et al. · ChemistrySelect · 2026

    Open access · CC BYRead the open copy →

  13. Hormone und Hautpigmentierung – Grundlagen und klinische Relevanz

    Markus Böhm · Die Dermatologie · 2026

    Review1 citations

  14. Keratinocyte–Melanocyte Signaling: Molecular Pathways, Pigmentary Disease, and Therapeutic Targets

    Samarth Dhingra · American journal of student research. · 2026

    Open accessRead the open copy →

  15. New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective

    Cornelia Dechant, Sebastian Wäscher, Francesca Granata et al. · Orphanet Journal of Rare Diseases · 2025

    Study in humansOpen access · CC BY1 citationsRead the open copy →

  16. From darkness to light: Case report on afamelanotide-treatment in a 9-year-old child with erythropoietic protoporphyria

    Anna‐Elisabeth Minder, Jasmin Barman‐Aksözen · JAAD Case Reports · 2025

    Case reportOpen access · CC BY2 citationsRead the open copy →

  17. Burden of illness and unmet needs in patients with erythropoietic protoporphyria and X-linked protoporphyria: A large US nationwide claims analysis

    Maral DerSarkissian, Chelsea Norregaard, Hela Romdhani et al. · Journal of Managed Care & Specialty Pharmacy · 2025

    Study in humans

  18. Polymorphism of Melanocortin Receptor Genes—Association with Inflammatory Traits and Diseases

    Mainak Bardhan, Ayush Anand, Amaan Javed et al. · Diseases · 2025

    ReviewOpen access · CC BY5 citationsRead the open copy →

  19. Melanocortin receptors in GtoPdb v.2025.3

    Vanni Caruso, Jeffrey B. Tatro, Helgi B. Schiöth et al. · IUPHAR/BPS Guide to Pharmacology CITE · 2025

    Open access · CC BY-SARead the open copy →

  20. Erythropoietic protoporphyria in childhood: clinical clues, missed diagnoses and emerging therapy

    Moritz Toenne, T. Schaefer · European Journal of Pediatrics · 2025

    Review2 citations

  21. Silica‐Assisted Solid‐Phase Peptide Synthesis (SiPPS)

    Nonsikelelo Nkwanyana, Ashish Kumar, Amit Chakraborty et al. · Journal of Peptide Science · 2025

    Open access · CC BY-NC-ND4 citationsRead the open copy →

  22. Afamelanotide in managing cutaneous phototoxicity in erythropoietic protoporphyria: a Scottish perspective

    Robert S Dawe, Alastair C. Kerr, Ewan Eadie et al. · Clinical and Experimental Dermatology · 2025

    Open access2 citationsRead the open copy →

  23. EMA , It's Time to Reconsider! 10 Years Afamelanotide for Treating Erythropoietic Protoporphyria

    Rocco A. Falchetto, Cornelia Dechant, Mårten Pettersson et al. · Photodermatology Photoimmunology & Photomedicine · 2025

  24. A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic in a tertiary referral centre

    Fei Ya Lai, Claire Quigley, Gregg Murray et al. · Skin Health and Disease · 2025

    Open access · CC BYRead the open copy →

  25. German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP )

    Bernhard Homey, Kathrin Schelonke, C Schlegel et al. · Photodermatology Photoimmunology & Photomedicine · 2025

    Study in humansOpen access · CC BY-NC-ND7 citationsRead the open copy →

  26. Treatment advances in Vitiligo: An Updated Review

    Ishrat Binti Ismail, Yasmeen Jabeen Bhat, Mohd Shurjeel Ul Islam · Dermatology Practical & Conceptual · 2025

    ReviewOpen access · CC BY-NC15 citationsRead the open copy →

  27. Triethyl phosphate (TEP) – dimethylsulfoxide (DMSO), as a green solvent mixture for solid-phase peptide synthesis (SPPS)

    Sikabwe Noki, Luana Lastella, Simona Şerban et al. · Green Chemistry Letters and Reviews · 2024

    Open access · CC BY-NC13 citationsRead the open copy →

  28. Discovery of MT-7117 (Dersimelagon Phosphoric Acid): A Novel, Potent, Selective, and Nonpeptidic Orally Available Melanocortin 1 Receptor Agonist

    Atsushi Satō, Kenji Morokuma, Takashi Adachi et al. · Journal of Medicinal Chemistry · 2024

    Study in humans6 citations

  29. 461 The effects of afamelanotide on UVR-induced DNA damage, acute inflammatory and DNA repair responses in human skin

    M. Peake, Kirsty J. Rutter, Liezel L. Griffin et al. · Journal of Investigative Dermatology · 2024

    Open accessRead the open copy →

  30. Mechanistic Model for Drug Release from PLGA-Based Biodegradable Implants for In Vitro Release Testing: Development and Validation

    Naresh Mittapelly, Alexandre Djehizian, Krishna Chaitanya Telaprolu et al. · ACS Applied Bio Materials · 2024

    Open access · CC BY-NC-ND18 citationsRead the open copy →

  31. The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria

    Louisa G. Kluijver, Margreet A.E.M. Wagenmakers, J.H.P. Wilson et al. · The Journal of Clinical Endocrinology & Metabolism · 2024

    Study in humansOpen access · CC BY5 citationsRead the open copy →

  32. Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs)

    Nicholas A. Weirath, Carrie Haskell‐Luevano · ACS Pharmacology & Translational Science · 2024

    Open access5 citationsRead the open copy →

  33. Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management

    Anna‐Elisabeth Minder, Louisa G. Kluijver, Jasmin Barman‐Aksözen et al. · Liver International · 2024

    ReviewOpen access · CC BY27 citationsRead the open copy →

  34. Role of microneedling in vitiligo

    Aya Haggag, Yomna Mazid El‐Hamd Neinaa, Nagwa M. Elwan · International Journal of Dermatology Venereology and Leprosy Sciences · 2024

    Open accessRead the open copy →

  35. Health Threat in the Tanning Trend

    Mohammed Al Abadie · Dermatology and Dermatitis · 2024

    Open accessRead the open copy →

  36. Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort

    Rebecca Karp Leaf, Hetanshi Naik, Paul Yanning Jiang et al. · Life · 2024

    Open access · CC BY6 citationsRead the open copy →

  37. The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria: a multicentre cohort study

    Louisa G. Kluijver, Mitra Nekouei Shahraki, Margreet A.E.M. Wagenmakers et al. · British Journal of Dermatology · 2024

    Study in humansOpen access · CC BY4 citationsRead the open copy →

  38. Toward sustainable solid-phase peptide synthesis strategy – in situ Fmoc removal

    Ndumiso Mthethwa, K. P. Nandhini, Ashish Kumar et al. · Green Chemistry Letters and Reviews · 2024

    Open access · CC BY18 citationsRead the open copy →

  39. A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo

    Alireza Jafarzadeh, Arash Pour Mohammad, Mina Khosravi et al. · Skin Research and Technology · 2024

    Systematic reviewOpen access · CC BY30 citationsRead the open copy →

  40. Treatment strategy for erythropoietic protoporphyria accompanied by severe abdominal pain and liver injury

    Xiaoxin Wu, Xiumei Zhou, Shuai Zhao et al. · Portal hypertension & cirrhosis · 2024

    Open access · CC BY-NC-NDRead the open copy →

Each list shows up to 40 papers.See all 156 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:27 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.